VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | CDKN2A and TP53 mutation in HPV-negative HNSCC

Barbara Burtness, MD, of Yale Cancer Center, New Haven, CT, discusses the predicitive value of TP53 and CDKN2 mutations in determining tumor mutational burden in HPV negative head and neck squamous cell carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter